Mobile App Click here to download our Mobile App for iOS or Android
Not a member? Sign up for free!

Consumers With Schizophrenia: Tools For Relapse Reduction

Congress Exhibits | September 12, 2017 2:00 pm to 3:30 pm ET


September 12, 2017 – Free Executive Web Briefing Sponsored By Otsuka Pharmaceutical Development & Commercialization, Inc. Frameworks In Health & Quality Program

The risk of relapse is great for those diagnosed with schizophrenia, with the 1-year rate as high as 50% and the 5 year rate as high as 80% – making long-term therapy goals difficult to reach.1,2 In 2010, there were over 397,000 hospital stays for schizophrenia and other psychotic disorders and of those, approximately 1 in 4 (22%) were readmitted within 30 days.3 Patient wellness, reducing severity of symptoms, and reduced risk of future relapses are critical therapy outcomes.4,5

Just as significant is the cost of mental health care and treatment services which are estimated at $113 billion annually. The cost increases to $300 billion annually when you add in the cost of lost earnings and wages, and disability benefits.4 The direct costs for schizophrenia in the U.S. were estimate at $47 billion (in 2013 dollars).6

Join Heidi Waters, PhD, Director of Outcomes Management at Otsuka Pharmaceutical Development & Commercialization, Inc. and co-presenter, Annie Medina, MBA, ACNP-BC, Senior Associate at OPEN MINDS, for this session to learn about the Frameworks In Health & Quality disease management program focusing on schizophrenia relapse reduction. In this session, faculty will discuss a program and strategies for relapse reduction with topics including:

  • Current trends in population health management and health system services for the management of schizophrenia
  • Models for improving outcome of consumers with schizophrenia through medication adherence, medication reconciliation, and transition of care support
  • Education support resources for all stakeholders involved in the management of schizophrenia


The co-presenter is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.

  1. Schennach R. et al. Psychiatry SeN. 2012: 63(1):87-90.
  2. Robinson D. et al. Arch Gen Psychiatry. 1999: 56(3):241-247.
  3. Elixhauser A. Steiner C. Readmissions to U.S. Hospitals by Diagnosis. 2010. HCUP Statistical Stief #153. April 2013. Ag en Of fOf Healthcare Research and Quality. Roct:ville MD. 153.pdf. Accessed January 27 2014.
  4. Lehman AF et al. Practice Guideline for the Treatment of Patients with Schizophrenia. JI. Formulation and Implementation of a Treatment P lan. Arlington, VA : American Psychiatric Publishing. Inc.: 2004.
  5. Faltai P. et al. World J Biol Psychiatry. 2006: 7(1): 5–40.
  6. Cloutier M. et al. J Clin Psychiatry. 2016: TT(6): 764-TT1.

Event Speakers

Heidi C. Waters, MBA, PhD
Featured Speaker

Heidi Waters, MBA, PhD, partners with payers and providers to develop unbranded health services research to improve the process of care and optimize outcomes for consumers with serious mental illness and other conditions that Otsuka products help treat. Prior to joining Otsuka, Heidi worked for Ethicon as Global Franchise Director, Health Economics and Director, Health Economics for Centocor Ortho Biotech, both Johnson & Johnson companies.

Annie Medina, MBA, ACNP-BC
Featured Speaker

Annie Medina, MBA, ACNP-BC, brings over ten years of experience in the health and human services industry to the OPEN MINDS team. Her expertise spans both clinical and operational functions and is focused in business operations, strategic planning, project management, training and curriculum development, and policy and procedure design. Ms. Medina currently serves as a Senior Associate at OPEN MINDS. In addition to her work with OPEN MINDS, Ms. Medina is a Hospice Nurse Practitioner for Crater Community Hospice.

Prior to joining the OPEN MINDS team, Ms. Medina was the Chief Operating Officer for Poplar Springs Hospital, a member of Universal Health Services, based in Petersburg, Virginia. In this role, she was responsible for performance improvement, policy and procedure creation, and strategy development and implementation for the hospital’s Joint Commission and CMS regulatory surveys. Prior to this role, Ms. Medina was a MBA intern for the Popular Springs CEO where she focused on business development, process improvement, training tool development and evaluation of newly offered programs.